On February 7, 2022 Varsity Pharmaceuticals (Varsity), a biopharmaceutical company developing small molecule therapies that target treatment resistant cancers, reported that it has secured exclusive rights from Dana-Farber Cancer Institute, a world-leading cancer treatment and research institute, to develop and commercialize Novobiocin, a potential first-in-class DNA polymerase theta inhibitor for the treatment of Homologous Recombination (HR) deficient cancers (Press release, Varsity Pharmaceuticals, FEB 7, 2022, View Source [SID1234607809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Homologous Recombination deficiency is where the body is unable to repair double strand breaks in DNA due to mutations in genes such as BRCA1 and BRCA2. Pol-Theta is an enzyme that can repair double strand breaks that recently emerged as a new cancer specific DNA Damage Response target that compensates for the loss of HR function in HR deficient cancers such as ovarian, breast, pancreatic and prostate cancer. Whilst PARP enzyme inhibitors have seen some success in the treatment of HR deficient cancers, PARP inhibitor drug resistance is emerging as a significant barrier to their effectiveness.

Research led by Prof. Alan D. D’Andrea and published in Nature Cancer (Zhou et al. 2021) demonstrated that Novobiocin, a drug previously used as an antibiotic, is a potent Pol-Theta enzyme inhibitor that can be used alone or in combination with PARP inhibitors to treat HR-deficient tumors, even after they have become resistant to PARP inhibitor therapy.

More than 50% of primary ovarian cancers, 25% of breast cancers, and approximately 5% of pancreatic and prostate cancers are associated with HR deficiency. If development is successful, the Pol-Theta inhibitor Novobiocin could be a new treatment option for more than a 100,000 newly diagnosed cancer patients per year in the US alone. Varsity plans to start the first in-patient clinical studies of Novobiocin in 2022.

Varsity adds Novobiocin to a pipeline of small molecule candidates under development as new therapies for treatment resistant cancers.

On February 7, 2022 Evogene Ltd. (NASDAQ-GM: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments reported that it will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 25th at 9:00 Eastern (Press release, Evogene, FEB 7, 2022, View Source [SID1234607808]). The conference will span three days, starting on February 23rd until February 25th from 8:30AM until 5PM EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evogene’s presentation will be available by request to Aegis from February 23 to 25, 2022. The slide deck will also be made available on Evogene’s website at View Source

To access the event, please download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual Conference Calendar

On February 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, reported that CEO, Dr James Garner, will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022 (Press release, Kazia Therapeutics, FEB 7, 2022, View Source [SID1234607807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hosted annually by the Biotechnology Innovation Organization (BIO) for over 20 years, the conference is focused on emerging public and private companies, offering a meeting place for institutional investors, industry analysts, and senior biotech executives. The conference draws biotech companies looking to make the connections needed to take their products to the next phase.

Kazia will be presenting in person on day one of the conference, Monday, 14 February. The presentation will provide an update on recent progress with Kazia’s two clinical-stage oncology programs and will cover some of the important catalysts expected during 2022.

On February 7, 2022 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported it will be participating virtually in the following investor conferences (Press release, Guardant Health, FEB 7, 2022, View Source [SID1234607806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

11th Annual SVB Leerink Global Healthcare Conference
Fireside Chat on Wednesday, February 16 th at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time
Citi 2022 Healthcare Conference
Fireside Chat on Thursday, February 24 th at 11:45 a.m. Pacific Time / 2:45 p.m. Eastern Time
Cowen 42nd Annual Health Care Conference
Fireside Chat on Tuesday, March 8 th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time
Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.guardanthealth.com.

On February 7, 2022 Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, reported that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, Feb. 17, 2022, at 3:00 p.m. Eastern time (Press release, Castle Biosciences, FEB 7, 2022, View Source [SID1234607805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at View Source A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.